BI's Jardiance Finally Wins FDA Green Light

August 1, 2014 5:41 PM

21 0

The FDA has finally okayed the SGLT2 inhibitor empagliflozin (Jardiance) for type 2 diabetes, the agency announced.

Approval follows the results of seven clinical trials totaling 4,480 patients with type 2 diabetes, the pivotal trials of which showed that the drug outperformed placebo in improving glycemic control as measured with HbA1c, the agency said.

Also read: FDA Approves First Nonopioid Treatment for Opioid Withdrawal Symptoms

Read more

To category page